ReviewMolecular cancer2018
Thyroid cancers of follicular origin in a genomic light: in-depth overview of common and unique molecular marker candidates.
Review in Molecular cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Delay of initial radioactive iodine therapy beyond 3 months has no effect on clinical responses and overall survival in patients with thyroid carcinoma: A cohort study and a meta-analysis.Cancer medicine · 2022Pooled it
- Trends and cross-country inequalities in the global burden of thyroid cancer, 1990-2021: A population-based study.Medicine · 2026Article
- Thyroid Collision Carcinoma: A Case Report.Iranian journal of pathology · 2026Article
- Somatic Mutational Landscape in Follicular Thyroid Cancer: Insights from AACR GENIE Data.Journal of personalized medicine · 2025Article
- Associations of light at night exposure and environmental pollutants with risk for thyroid cancer in Fujian, China: a spatio-temporal analysis.BMC public health · 2025Article
- Learning the cellular origins across cancers using single-cell chromatin landscapes.Nature communications · 2025Article
- Multi-omics clustering analysis carries out the molecular-specific subtypes of thyroid carcinoma: implicating for the precise treatment strategies.Genes and immunity · 2025Article
- The Genomic Landscape of Benign and Malignant Thyroid Tumors from Individuals Carrying Germline PTEN Variants Is Distinct from Sporadic Thyroid Cancers.Cancer research · 2024Article
- Article
- [Female reproductive function after radioiodine therapy for differentiated thyroid carcinoma].Problemy endokrinologii · 2024Review
- Assessing and projecting the global burden of thyroid cancer, 1990-2030: Analysis of the Global Burden of Disease Study.Journal of global health · 2024Article
- Comparative analysis through propensity score matching in thyroid cancer: unveiling the impact of multiple malignancies.Frontiers in endocrinology · 2024Article
- Burden of thyroid cancer in China and worldwide from 1990 to 2021: observation, comparison, and forecast from the Global Burden of Disease Study 2021.Frontiers in endocrinology · 2024Article
- Osseous Metastases in Thyroid Cancer: Unveiling Risk Factors, Disease Outcomes, and Treatment Impact.Cancers · 2023Article
- Neutrophil extracellular traps and neutrophil-related mediators in human thyroid cancer.Frontiers in immunology · 2023Article
- Curcumin Induces Ferroptosis in Follicular Thyroid Cancer by Upregulating HO-1 Expression.Oxidative medicine and cellular longevity · 2023Article
- Clinical outcomes of multifocal papillary thyroid cancer: A systematic review and meta-analysis.Laryngoscope investigative otolaryngology · 2022Review
- PAX8 in the Junction between Development and Tumorigenesis.International journal of molecular sciences · 2022Review
- Elevated LINC00894 relieves the oncogenic properties of thyroid cancer cell by sponging let-7e-5p to promote TIA-1 expression.Discover oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, thyroid malignances have become more prevalent, especially among women. The most common sporadic types of thyroid tumors of follicular origin include papillary, follicular and anaplastic thyroid carcinomas. Although modern diagnosis methods enable the identification of tumors of small diameter, tumor subtype differentiation, which is imperative for the correct choice of treatment, is still troublesome. This review discusses the recent advances in the field of molecular marker identification via next-generation sequencing and microarrays. The potential use of these biomarkers to distinguish among the most commonly occurring sporadic thyroid cancers is presented and compared. Geographical heterogeneity might be a differentiator, although not necessarily a limiting factor, in biomarker selection. The available data advocate for a subset of mutations common for the three subtypes as well as mutations that are unique for a particular tumor subtype. Tumor heterogeneity, a known issue occurring within solid malignancies, is also discussed where applicable. Public databases with datasets derived from high-throughput experiments are a valuable source of information that aid biomarker research in general, including the identification of molecular hallmarks of thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.